Artivion (NYSE:AORT) EVP Lance Berry Sells 4,485 Shares

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,485 shares of Artivion stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $160,069.65. Following the transaction, the executive vice president directly owned 143,965 shares of the company’s stock, valued at approximately $5,138,110.85. This represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Artivion Price Performance

NYSE AORT traded up $0.98 during trading hours on Thursday, reaching $36.76. The company’s stock had a trading volume of 30,985 shares, compared to its average volume of 389,761. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The company’s 50-day moving average is $42.27 and its two-hundred day moving average is $43.08. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The stock has a market cap of $1.76 billion, a PE ratio of 183.81 and a beta of 1.59.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s quarterly revenue was up 19.2% compared to the same quarter last year. Analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Hedge Funds Weigh In On Artivion

Large investors have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd grew its position in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth $27,000. Larson Financial Group LLC boosted its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. USA Financial Formulas boosted its holdings in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the subject of a number of research reports. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Canaccord Genuity Group dropped their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.